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Cystic ﬁbrosis (CF) is a disease marked by repeated acute pulmonary exacerbations of infections, often
caused by Pseudomonas aeruginosa and Burkholderia cepacia. As antibiotic susceptibility declines, dose
optimization must be considered to provide adequate pharmacodynamic exposure. We report three
cases of CF exacerbations in adults caused by multi-drug resistant P. aeruginosa and B. cepacia. Each case
required dosing strategies greater than currently recognized in package inserts: meropenem 3000 mg
every 8 h (3-hour infusion) and doripenem 2000 mg every 8 h (4-hour infusion). Pharmacokinetic
analyses demonstrated that targeted pharmacodynamic exposures were achieved against most of the
organisms, resulting in clinical improvements despite laboratory reported resistance. The high-dose,
prolonged infusion regimens were well tolerated demonstrating that pharmacodynamically optimized
carbapenem regimens may be used safely and effectively in patients with limited conventional treatment
options.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disorder involving
many organs, but the effects on the lungs accounts for much of the
morbidity and mortality in affected patients.1 Repeated infection
and inﬂammation are the key components leading to a decline in
lung function. Moreover, due to numerous antibiotic courses over
their lives, the majority of CF patients are chronically infected with
highly resistant organisms, such as Pseudomonas aeruginosa, Bur-
kholderia cepacia, and other non-fermentative Gram-negative rods.
When the bacterial inoculum becomes large enough, acute
pulmonary exacerbations occur, requiring intensive parenteral
antimicrobial therapy. Unfortunately, the success of this therapy is
frequently hindered by the reduced potency of conventional anti-
microbial regimens due to resistance.
Carbapenems, and in particular meropenem, are commonly
prescribed for adults with CF because of their potent in vitro
activity against a number of Gram-negative rods, including P. aer-
uginosa and B. cepacia, as well as their tolerability at standard
dosages. Like other beta-lactam antibiotics, optimal bactericidal: þ1 860 545 3992.
u).
rved.activity for carbapenems is achieved when the amount of time that
free drug concentrations remain above the minimum inhibitory
concentration (MIC) (fT>MIC) of the pathogen exceeds 40% of the
dosing interval. For organisms with higher MICs, this critical
exposure can be achieved using higher doses, prolonged or
continuous infusions, or a combination of these.2 When adminis-
tered as a 3 h prolonged infusion to healthy volunteers, mer-
openem 2000 mg every 8 h achieved 73% fT>MIC at the
susceptibility breakpoint for P. aeruginosa (4 mg/ml) compared with
58% fT>MIC for the conventional 0.5 h dosing regimen.3 Despite
greater doses, prolonged infusion meropenem regimens were well
tolerated by the healthy volunteers with no infusion related
adverse events reported. More recently, we have employed pro-
longed infusions of meropenem and cefepime for the empiric
therapy of ventilator-acquired pneumonia to account for increasing
MICs among causative pathogens at our institution.4
While greater antibiotic doses are not unusual for CF patients,
regimens are generally maxed out at the maximum daily package
insert dose. Higher doses must be given to achieve optimal phar-
macodynamic exposures when carbapenem MICs become
increasingly elevated into the resistant range and when other
therapeutic options are unavailable. Naturally, the issue of safety
and tolerability of these high dose regimens falls into question.
Herein, we describe the tolerability and successful treatment of
C.C. Bulik et al. / Respiratory Medicine CME 3 (2010) 146–149 147three hospitalized CF patients with high-dose, prolonged infusion
meropenem and doripenem regimens against multi-drug resistant
B. cepacia complex and P. aeruginosa.
2. Case Patient 1
A 41-year-old Caucasian female with CF was admitted to the
hospital with an acute pulmonary exacerbation presumed to be
due to multi-drug resistant B. cepacia complex, of which she has
historically been infected by. Her admission FEV1 was 0.83 (29%
predicted) and except for hyperglycemia due to Type 1 diabetes
and hyponatremia (serum sodium: 130 mmol/L), all blood labo-
ratory values were in normal limits. Due to experience with
previous exacerbations from B. cepacia complex resistant to all
antibiotics, she was prescribed an empiric regimen of meropenem
3000 mg administered every 8 h as a 3-hour infusion to target
a MIC of 32 mg/mL, plus trimethoprim-sulfamethoxazole 2 double
strength tablets twice daily. Three blood samples were collected
around the ﬁfth meropenem dose to determine the steady-state
meropenem exposure that was achieved. Samples were allowed
to clot and then centrifuged immediately to separate the serum.
Concentrations of meropenem in serum were determined using
a previously described validated high-pressure liquid chroma-
tography (HPLC) assay.5 The lower limit of detection for the assay
was 0.25 mg/ml. The intraday and interday coefﬁcients of variation
were no greater than 5.9%. Meropenem serum concentrations
were ﬁt to a one-compartment model with use of WinNonLin Pro,
version 5.0 (Pharsight Corp., Mountain View CA). Her pharma-
cokinetic proﬁle included a maximum concentration at the end of
the infusion of 68.1 mg/ml, volume of distribution of 13.5 L, and
serum half-life of 0.67 h. At the presumed MIC of 32 mg/ml, free
drug concentrations above the MIC were achieved for 38% of the
8-hour dosing interval (Fig. 1). The patient tolerated her medi-
cation regimen well with no complaints of any constipation,
diarrhea, nausea, vomiting, or headache attributed to the pro-
longed infusion meropenem. Her blood laboratory values
remained within normal limits. After 14 days of combination
therapy with meropenem and trimethoprim-sulfamethaxazole,
she improved clinically such that her discharge FEV1 was 0.97 or
31% predicted; she completed a 28 day course of antibiotics at
home. The susceptibility results of her admission sputum culture
resulted in two strains of B. cepacia complex resistant to all
antibiotics tested (meropenem and trimethoprim-sulfamethax-
azole MICs both > 32 mg/ml by E-test).Fig. 1. Serum concentration-time proﬁle of multiple doses meropenem 3000 mg
administered every 8 h as a 3-hour infusion to a 41 year old female with cystic ﬁbrosis
who had a Burkholderia cepacia pulmonary exacerbation. At a minimum inhibitory
concentration (MIC) of 32 mg/ml, free drug concentrations above the MIC were ach-
ieved for 38% of the dosing interval.3. Case Patient 2
A 22-year old Caucasian male with CF was admitted to the
hospital with an acute pulmonary exacerbation due to P. aerugi-
nosa. His admission FEV1 was 2.01 (43% predicted) and his white
blood cell count was 11.5103/mm3 (normal 4–11103/mm3)
with 88.3% granulation. Because he was recently treated with
doripenem 1000 mg every 8 h as a 4 h infusion two months earlier
during a prior hospitalization, he was prescribed an empiric
regimen of doripenem 2000 mg administered every 8 h as a 4-hour
infusion to target a doripenemMIC of 16 mg/ml, plus colistin 75 mg
via nebulizer twice daily, and intravenous tobramycin 10 mg/kg
once daily. Blood samples were collected around the ﬁfth dor-
ipenem dose to characterize steady-state pharmacokinetics and
achieved pharmacodynamic exposure. Concentrations of dor-
ipenem in serum were determined by a previously validated HPLC
assay.6 The interday and intraday coefﬁcients of variation were no
greater than 5.9%, and the lower limit of detection was 0.5 mg/ml.
Doripenem serum concentrations were ﬁt to a one-compartment
model resulting in the following pharmacokinetic proﬁle:
maximum concentration of 23.7 mg/ml, volume of distribution of
29.5 L, and serum half-life of 1.04 h. His sputum culture from the
ﬁrst day of admission conﬁrmed infection with three strains of
multidrug resistant P. aeruginosa all reported as ‘‘non-susceptible’’
to doripenem. MICs were conducted by E-Test methodology. Two
strains were non-mucoid and had doripenem MICs of 8 mg/mL and
> 32 mg/ml. The third strain was mucoid with a doripenem MIC of
3 mg/ml. At these MICs, his doripenem regimen achieved 70% (MIC
of 8 mg/ml), 85% (MIC of 3 mg/ml), and 0% fT>MIC (MIC> 32 mg/ml)
against his three P. aeruginosa isolates (Fig. 2). He tolerated the
increased doses of doripenem without any complaints of nausea,
vomiting, or headache. The patient completed a 14 day antibiotic
course and responded well, remaining afebrile throughout his
hospitalization. His discharge FEV1 was 2.13 (45% predicted).
4. Case Patient 3
A 20-year old Caucasian female with CF was admitted with an
acute pulmonary exacerbation due to presumed B. cepacia complex.
On admission, all blood laboratory values were within normal
limits, and her FEV1 was 2.95 (51% predicted). Because of her
history of prior exacerbations with B. cepacia complex resistant to
all tested antimicrobials, she was started on doripenem 2000 mg
administered every 8 h as a 4-hour infusion to target a doripenemFig. 2. Serum concentration-time proﬁle of multiple doses doripenem 2000 mg
administered every 8 h as a 4-hour infusion in a patient with cystic ﬁbrosis who had
a Pseudomonas aeruginosa pulmonary exacerbation. At MICs of 3, 8, and 32 mg/ml, free
drug concentrations above the MIC were achieved for 85%, 70%, and 0% of the dosing
interval, respectively.
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240 mg every 8 h, and intravenous tobramycin 10 mg/kg for one
dose. Blood samples were collected around the third doripenem
dose to determine pharmacokinetics and achieved exposure. Dor-
ipenem serum concentrations were ﬁt to a one-compartment
model resulting in the following pharmacokinetic proﬁle:
maximum concentration of 47.9 mg/ml, volume of distribution of
10.7 L, and serum half-life of 0.73 h. Her sputum culture from the
ﬁrst day of admission conﬁrmed infection with 2 strains of B.
cepacia complex resistant to all antimicrobials tested. Doripenem
MICs were conducted by E-Testmethodology. At a doripenemMIC
of 32 mg/ml, free drug concentrations above the MIC were achieved
for 34% of the dosing interval (Fig. 3). The patient tolerated the
increased doses of doripenem well without any complaints of
nausea, vomiting, or headache. She improved clinically such that
her discharge FEV1 was 2.95 (52% predicted); however, after nine
days of antibiotic treatment, she developed Clostridium difﬁcile
infection, which she has had a history of acquiring during previous
antibiotic courses. Her doripenem dosage was reduced to 1000 mg
every 8 h (4 h infusion) for ﬁve additional days, and shewas treated
with oral vancomycin until improvement and discharge.
5. Discussion
Although carbapenems are commonly used to treat CF exacer-
bations due to P. aeruginosa and B. cepacia, their continued use can
result in the development of resistance. Pharmacodynamic princi-
ples have historically been applied to carbapenems, as well as other
beta-lactams, by administering these antibiotics as continuous or
prolonged infusions tomaximize the time above theMIC and garner
a positive clinical response in CF patients.7–11 However, the litera-
ture is absent of situations involving the safe and effective treatment
of highly resistant organisms with carbapenem regimens above the
maximum approved dose in the FDA package insert. Despite
administration of dailydoses greater thanpreviously reported in the
literature or the package insert, these three CFadults tolerated these
regimens well, had no detrimental changes in baseline laboratory
values, and achieved peak concentrations consistent with lower
doses when administered as standard 0.5 h infusions.
Toxicity is the primary concern when prescribing large doses of
any antibiotic for use in complicated infections. The most common
adverse events associated with carbapenems at standard dosages
are usually mild and self-limiting, including nausea, vomiting,
diarrhea, rash, transient increases in liver enzyme concentrations,
and infusion-site irritation.12,13 The development of seizures isFig. 3. Serum concentration-time proﬁle of multiple doses doripenem 2000 mg
administered every 8 h as a 4-hour infusion in a patient with cystic ﬁbrosis who
had a Burkholderia cepacia complex pulmonary exacerbation. At MICs of 4, 8, 16,
and 32 mg/ml, free drug concentrations above the MIC were achieved for 78%, 69%,
56%, and 34% of the dosing interval, respectively.considered the more serious, albeit infrequent, adverse reaction
associated with carbapenem use. Each carbapenem demonstrates
a different neurotoxic potential with imipenem having the greatest
ability to inhibit g-aminobutyric acid (GABA) receptor binding, the
suggested mechanism of convulsive activity, where as meropenem
and doripenem have signiﬁcantly lower binding afﬁnities.14 While
GABA binding afﬁnity and convulsive activity are clearly dose
dependent, animal studies are conducted by using intravenous or
intracerebroventricular bolus, thus the true effect is believed to be
most related to immediate peak concentrations.14 As a result, pro-
longing the carbapenem infusion for 3 to 4 h lowers the peak
concentration and therefore, may reduce the likelihood of convul-
sive activity.15 The lack of adverse reactions, especially neurotoxic
events, seen with the increased doses used in our three cases is
supportive of this. Indeed, peak concentrations for meropenem in
adults with CF receiving 2000 mg every 8 h as 0.5 h infusions were
11313 mg/ml,16 where as Case Patient 1, who received 3000 mg as
a 3 h infusion, achieved a steady-state peak concentration at the
end of the infusion of 68.1 mg/ml. There are no pharmacokinetic
data for doripenem in adults with CF, however, healthy volunteers
receiving 1000 mg every 8 h as 1 h infusions achieved average peak
concentrations of 43.0 3.96 mg/ml,17 which are similar to the peak
concentrations of Case Patient 3 (47.9 mg/ml), and twice as high as
Case Patient 2 (23.7 mg/ml), both of whom received 2000 mg as 4 h
infusions.
In addition to providing toxicodynamic beneﬁts, the reason for
administering these carbapenems by prolonged infusion was
foremost to increase the free drug time above the MIC against
organisms with MICs above the susceptibility breakpoint. For
example, the current FDA approved dose of meropenem 1000 mg
administered every 8 h as a 0.5 h infusion has been shown to have
a 64% probability of attaining bactericidal exposures (i.e., 40%
fT>MIC) at MICs of 4 mg/ml using patient pharmacokinetics.18
Simply extending the infusion duration to 3 h increased this
probability to 90%. Moreover, prolonging the infusion combined
with higher doses can increase the probability of achieving bacte-
ricidal exposure against pathogens with meropenem MICs above
the susceptibility breakpoint, as was the case with an adult CF
patient with meropenem intermediate resistant B. cepacia complex
(MIC¼ 8 mg/ml), who had a successful therapeutic response after
achieving 52% fT>MIC upon receiving 2000 mg every 8 h as 3 h
infusions.9 Case Patient 1 in this series had a B. cepacia infection
with a presumed meropenem MIC of 32 mg/ml based on previous
microbiology results. She achieved 38% fT>MIC after receiving
3000 mg every 8 h (3 h infusions). MIC testing of her pathogen
revealed a meropenem MIC greater than 32 mg/ml, so we were not
able to calculate her achieved exposure precisely. Nonetheless, she
responded to this regimen in combination with trimethoprim/
sulfamethoxazole. To our knowledge, this is the highest daily
cumulative dose of meropenem (9000 mg per day – importantly,
administered by prolonged infusion) reported in the literature and
was well tolerated by the patient with no gastrointestinal, neuro-
toxic, or laboratory reported adverse events noted.
Doripenem, a novel carbapenem, is currently approved in the
United States at a dose of 500 mg every 8 h as a 1 h infusion for the
treatment of complicated intra-abdominal infections and compli-
cated urinary tract infections including pylonephritis. However,
pharmacokinetics and safety have been demonstrated at doses of
1000 mg every 8 h (1 h infusion) in healthy volunteers.17 It has also
been studied for use in ventilator-associated pneumonia at a dose
of 500 mg every 8 h as a 4-hour infusion and demonstrated
comparable safety to imipenem.19 Although current MIC distribu-
tions for P. aeruginosa demonstrate that the majority of Gram-
negative organisms are susceptible to conventional doses of dor-
ipenem,20 multiple pharmacokinetic simulation studies suggest
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fT>MIC against pathogens with MICs greater than 4 mg/ml.21–23 To
address this issue, an increased dose of doripenem 1000 mg every
8 h given as a 4-hour infusion is currently being studied for use in
ventilator associated pneumonia (http://clinicaltrials.gov/). Based
on presumed high MICs for Case Patient 2’s P. aeruginosa, we
administered doripenem 2000 mg every 8 h as a 4-hour infusion,
and achieved greater than 70% fT>MIC at MICs up to 8 mg/ml. Of
note, a higher dose would have been necessary in this patient to
provide concentrations above the MIC for his isolate at 32 mg/ml.
Case Patient 3 was tiny (w90 pounds), and thus a similar dose of
2000 mg every 8 h as a 4-hour infusion achieved a higher peak
concentration and fT>MIC exposure that was near optimal up to
MICs of 32 mg/ml. Both patients demonstrated successful responses
to these regimens in combination with other anti-Pseudomonas or
anti-B. cepacia antibiotics, and importantly, tolerated these regi-
mens well.
6. Conclusion
Patients with CF are often infected with multidrug resistant
Gram-negative rods, including P. aeruginosa and B. cepacia complex.
While carbapenems are widely used to treat these pathogens when
susceptible, higher dosages may be required when resistance is
apparent and fewother antibiotic options are available. In this small
case series,wehavedemonstrated the successful and safe utilization
ofmaximal daily doses of 9000 mg formeropenem and 6000 mg for
doripenem, when administered by 3- and 4-hour prolonged infu-
sions, respectively. Further systematic evaluation of these dosing
regimens in clinical trials of adult CF patients is advocated.
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